Balaxi Pharma
Balaxi Pharma Q2 FY26: Revenue ₹56.17 Cr, PAT ₹0.21 Cr
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaxi Pharma's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue for Q2 FY26: ₹56.17 crore - Revenue for Q2 FY25: ₹77.38 crore - Year-on-year revenue change: -27.4% - No explicit sales volume figures are stated in the presentation. - There is no direct explicit outlook for revenue or volumes mentioned. Q2 FY26 Financials vs Q2 FY25 (Page 20): - EBITDA: ₹1.17 crore, down 88.9% YoY from ₹10.59 crore - EBITDA Margin: 2.1%, decreased by 1158 bps YoY from 13.7% - Profit After Tax (PAT): ₹0.21 crore, down 95.4% YoY from ₹4.59 crore - PAT Margin: 0.4%, decreased by 550 bps YoY from 5.9% - Operating Margin (EBITDA margin) explicitly reported as 2.1% for Q2 FY26 (Page 20).
From Balaxi Pharma's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Revenue for Q2 FY26: ₹56.17 crore
- Revenue for Q2 FY25: ₹77.38 crore
- Year-on-year revenue change: -27.4%
- No explicit sales volume figures are stated in the presentation.
- There is no direct explicit outlook for revenue or volumes mentioned.
- However, management comments (Page 19) note challenges in Q2 FY26 due to market softness, working capital pressure, and logistics delays.
2 more points from Balaxi Pharma's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Balaxi Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex plans include establishing the Company’s first pharmaceutical formulation manufacturing facility in Hyderabad (Page 14).
- The manufacturing facility is located in a Pharma SEZ near Hyderabad, focused on General Oral Solid Dosage (OSD) formulations for Latin America and Africa markets (Pages 9-11).
- Facility commissioning is complete with Plant Qualification and Validation done (Page 9).
- This backward integration aims to improve control, regulatory compliance, reduce time-to-market, and enhance profit margins (Pages 8-9).
2 more points from Balaxi Pharma's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Balaxi Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Balaxi Pharma's call on order book
Pro opens every point from 15K+ earnings calls
Balaxi Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹73 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaxi Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Emcure Pharmaceuticals Ltd (Q2 FY26)
Emcure Pharmaceuticals delivered a strong Q2 FY26 with 25% PAT growth, reporting highest quarterly profit of INR 251 crores. Key concall takeaways from Emcure…
Arthneeti Pro · Annual
Balaxi Pharma and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Balaxi Pharma Q2 FY26 results?
Revenue for Q2 FY26: ₹56.17 crore - Revenue for Q2 FY25: ₹77.38 crore - Year-on-year revenue change: -27.4% - No explicit sales volume figures are stated in the presentation. - There is no direct explicit outlook for revenue or volumes mentioned. Q2 FY26 Financials vs Q2 FY25 (Page 20): - EBITDA: ₹1.17 crore, down 88.9% YoY from ₹10.59 crore - EBITDA Margin: 2.1%, decreased by 1158 bps YoY from 13.7% - Profit After Tax (PAT): ₹0.21 crore, down 95.4% YoY from ₹4.59 crore - PAT Margin: 0.4%, decreased by 550 bps YoY from 5.9% - Operating Margin (EBITDA margin) explicitly reported as 2.1% for Q2 FY26 (Page 20).
What is Balaxi Pharma share price analysis?
Balaxi Pharma currently shows a neutral. The stock trades at a P/E of 50.2 with a market cap of ₹122 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaxi Pharma planning capital expenditure?
Capex plans include establishing the Company’s first pharmaceutical formulation manufacturing facility in Hyderabad (Page 14).
Keep Balaxi Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.